Major depressive disorder (MDD) is one of the most disabling psychiatric disorders.
Approximately one‐third of the patients with MDD are treatment resistant to the current …

Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published
treatment guidelines for bipolar disorder in 2005, along with international commentaries and …

BackgroundRecent open-label trials show that psychedelics, such as ayahuasca, hold
promise as fast-onset antidepressants in treatment-resistant depression. MethodsTo test the …

Background Terminally ill patients may experience existential distress, depression, or
anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or …

This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …

Mental disorders are rising while development of novel psychiatric medications is declining.
This stall in innovation has also been linked with intense debates on the current diagnostics …

The efficacy of standard antidepressants is limited for many patients with mood disorders
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …

Background In the past two decades, subanaesthetic doses of ketamine have been
demonstrated to have rapid and sustained antidepressant effects, and accumulating …

Depression and type 2 diabetes (T2D) are highly comorbid disorders that carry a large
public health burden. However, there is a clear lack of knowledge of the neural pathological …